New PET scan could sharpen detection of neuroendocrine tumors

NCT ID NCT07102056

Not yet recruiting Diagnosis Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test a new type of PET scan using a radioactive tracer called 18F-Octreotide in 152 people with or suspected of having neuroendocrine tumors. The goal is to see if this scan can more accurately locate tumors, guide treatment decisions, and help predict how the disease will progress. Researchers will also explore its use in measuring tumor size, grading, and identifying genetic types.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Octreotide (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors more accurately locate neuroendocrine tumors, choose the best treatment, and predict patient outcomes.
What could go wrong: This is an early-stage study with only 152 participants, so results may not apply to everyone. The new scan may not be significantly better than current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS

More trials for these conditions

Other studies related to the condition(s) this trial covers.